ReviewAnnals of transplantation2026
Urinary Microbiome Characteristics in Kidney Transplant Recipients and Their Clinical Implications: A Narrative Review.
Review in Annals of transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-throughput sequencing has overturned the long-standing "sterile urine" paradigm and revealed a low-biomass yet clinically informative urinary tract microbiota. In kidney transplant recipients, immunosuppression, perioperative instrumentation, and antibiotic exposure can reshape urinary microbial communities; however, reported signatures remain heterogeneous across cohorts and methodologies. This narrative review synthesizes evidence on: (1) baseline urobiome patterns and major determinants of inter-individual variability, (2) post-transplant drivers of dysbiosis, and (3) associations between urobiome dynamics and key transplant outcomes, including urinary tract infection (UTI), acute rejection (AR), and chronic allograft dysfunction such as interstitial fibrosis and tubular atrophy (IF/TA). Across studies, dysbiosis commonly manifests as reduced diversity, depletion of putatively protective taxa, and enrichment of opportunistic pathogens; several longitudinal cohort studies further suggest that microbiome shifts can precede clinical events, supporting a potential window for risk stratification and early surveillance. We also summarize translational research directions, including integration of urinary microbial profiles with host biomarkers and multi-omics readouts, as well as microbiome-sparing strategies (antimicrobial stewardship, targeted probiotics/synbiotics, and dietary modulation). Finally, we highlight methodological challenges unique to low-biomass urine samples - especially contamination control, negative controls, and transparent reporting - that are essential for improving reproducibility and enabling clinical implementation. This review aims to provide an up-to-date, clinically oriented synthesis of the post-transplant urobiome and to propose methodological and translational priorities for future research and implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.